US Stock MarketDetailed Quotes
LXEO Lexeo Therapeutics
- 6.470
- +0.270+4.35%
Close Nov 22 16:00 ET
- 6.470
- 0.0000.00%
Post 20:01 ET
213.94MMarket Cap-2470P/E (TTM)
6.720High6.200Low170.47KVolume6.230Open6.200Pre Close1.11MTurnover1.00%Turnover RatioLossP/E (Static)33.07MShares22.33052wk High1.54P/B109.84MFloat Cap5.77052wk Low--Dividend TTM16.98MShs Float22.330Historical High--Div YieldTTM8.39%Amplitude5.770Historical Low6.482Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Lexeo Therapeutics Stock Forum
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints
Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling...
NEWS
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
No comment yet